Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAF(V600)-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor

PURPOSE: Preclinical and early clinical studies have demonstrated that initial therapy with combined BRAF and MEK inhibition is more effective in BRAF(V600)-mutant melanoma than single-agent BRAF inhibitors. This study assessed the safety and efficacy of dabrafenib and trametinib in patients who had...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Clin Oncol
Asıl Yazarlar: Johnson, Douglas B., Flaherty, Keith T., Weber, Jeffrey S., Infante, Jeffrey R., Kim, Kevin B., Kefford, Richard F., Hamid, Omid, Schuchter, Lynn, Cebon, Jonathan, Sharfman, William H., McWilliams, Robert R., Sznol, Mario, Lawrence, Donald P., Gibney, Geoffrey T., Burris, Howard A., Falchook, Gerald S., Algazi, Alain, Lewis, Karl, Long, Georgina V., Patel, Kiran, Ibrahim, Nageatte, Sun, Peng, Little, Shonda, Cunningham, Elizabeth, Sosman, Jeffrey A., Daud, Adil, Gonzalez, Rene
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Clinical Oncology 2014
Konular:
ORIGINAL REPORTS
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4226803/
https://ncbi.nlm.nih.gov/pubmed/25287827
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.57.3535
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller